

# Contents

List of abbreviations	viii	Other rare benign neoplasms	66
Foreword	ix	Sample reports	67
<b>1 Introduction to the WHO Reporting System for Pancreaticobiliary Cytopathology</b>	<b>1</b>	<b>5 Diagnostic category: Atypical</b>	<b>71</b>
Background	2	Introduction	72
The role of pancreaticobiliary cytopathology	4	Definition	72
Integration of clinical, radiological, and key FNAB cytopathological features with ancillary testing in a diagnostic approach	5	Discussion and background	73
Diagnostic categories and report structure	6	Risk of malignancy and management recommendations	75
Risk of malignancy and management recommendations	9	Sample reports	76
<b>2 Pancreaticobiliary cytopathology techniques</b>	<b>11</b>	<b>6 Diagnostic category: Pancreaticobiliary neoplasm, low-risk/grade</b>	<b>77</b>
Sampling methods and tissue triage		Introduction	78
FNAB techniques and specimen management for solid pancreatic masses	12	Definition	78
FNAB techniques and specimen management for pancreatic cysts	13	Discussion and background	79
FNAB techniques and specimen management for bile duct brushings	14	Risk of malignancy and management recommendations	80
Percutaneous FNAB and specimen management	16	Specific lesions	
Rapid onsite evaluation	17	Pancreatic intraepithelial neoplasia, low-grade	81
Ancillary testing		Biliary intraepithelial neoplasia, low-grade	83
Introduction: The role of ancillary testing	18	Pancreatic intraductal papillary mucinous neoplasm, low-grade	85
Immunocytochemistry	19	Intraductal papillary neoplasm of the bile duct, low-grade	87
In situ hybridization	23	Mucinous cystic neoplasm, low-grade	88
Molecular testing	26	Other lesions (including spindle cell tumours)	90
Biochemical testing of cyst fluid	29	Sample reports	91
<b>3 Diagnostic category: Insufficient/Inadequate/Non-diagnostic</b>	<b>31</b>	<b>7 Diagnostic category: Pancreaticobiliary neoplasm, high-risk/grade</b>	<b>93</b>
Introduction	32	Introduction	94
Definition	32	Definition	94
Discussion and background	33	Discussion and background	95
Risk of malignancy and management recommendations	35	Risk of malignancy and management recommendations	96
Sample reports	36	Specific lesions	
<b>4 Diagnostic category: Benign / Negative for malignancy</b>	<b>37</b>	Pancreatic intraepithelial neoplasia, high-grade	97
Introduction	38	Biliary intraepithelial neoplasia, high-grade	99
Definition	38	Pancreatic intraductal papillary mucinous neoplasm, high-grade	101
Discussion and background	39	Intraductal papillary neoplasm of the bile duct, high-grade	104
Risk of malignancy and management recommendations	40	Mucinous cystic neoplasm, high-grade	106
Benign non-neoplastic processes		Intraductal oncocytic papillary neoplasm	108
Normal pancreatic and biliary parenchyma and contaminants	41	Intraductal tubulopapillary neoplasm	110
Acute pancreatitis	44	Sample reports	112
Cholangitis	46	<b>8 Diagnostic category: Suspicious for malignancy</b>	<b>115</b>
Chronic pancreatitis	48	Introduction	116
Groove/paraduodenal pancreatitis	50	Definition	116
Autoimmune and IgG4-related pancreatitis	52	Discussion and background	117
Lymphoepithelial cyst	55	Risk of malignancy and management recommendations	119
Pseudocysts	57	Sample reports	120
Splenule (accessory spleen)	59	<b>9 Diagnostic category: Malignant</b>	<b>121</b>
Benign neoplastic processes		Introduction	122
Serous cystadenoma	61	Definition	122
Schwannoma	64	Discussion and background	123
Lymphangioma	65	Risk of malignancy and management recommendations	124

Specific lesions		Atypical	173
Cholangiocarcinoma	126	Pancreaticobiliary neoplasm, low-risk/grade	174
Pancreatic ductal adenocarcinoma	130	Pancreaticobiliary neoplasm, high-risk/grade	176
Pancreatic acinar cell carcinoma	139	Suspicious for malignancy	178
Neuroendocrine tumour	142	Malignant	179
Neuroendocrine carcinoma	146		
Pancreatoblastoma	148	<b>Contributors</b>	<b>181</b>
Solid pseudopapillary neoplasm	151	<b>Declaration of interests</b>	<b>183</b>
Pancreatic lymphomas	156	<b>Sources</b>	<b>185</b>
Metastases to the pancreas	159	<b>References</b>	<b>187</b>
Other lesions (including spindle cell tumours)	163	<b>Subject index</b>	<b>203</b>
Sample reports	166	<b>Previous volumes in the series</b>	<b>205</b>
<b>10 Management recommendations for each diagnostic category</b>	<b>169</b>		
Introduction	170		
Insufficient/Inadequate/Non-diagnostic	171		
Benign / Negative for malignancy	172		